# Impact of Remimazolam on Prognosis After Bladder Cancer Surgery

> **NCT04532606** · PHASE4 · RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 1128 (estimated)

## Conditions studied

- Benzodiazepines
- Bladder Cancer
- Delirium
- Surgery
- Cancer Recurrence

## Interventions

- **DRUG:** Remimazolam
- **DRUG:** Propofol

## Key facts

- **NCT ID:** NCT04532606
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-05
- **Primary completion:** 2025-10
- **Final completion:** 2026-10
- **Target enrollment:** 1128 (ESTIMATED)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04532606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04532606, "Impact of Remimazolam on Prognosis After Bladder Cancer Surgery". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04532606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*